Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine

被引:163
作者
Wang, DJ
Dowling, TC
Meadows, D
Ayala, T
Marshall, J
Minshall, S
Greenberg, N
Thattassery, E
Fisher, ML
Rao, K
Gottlieb, SS
机构
[1] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[2] Baltimore Vet Adm Med Ctr, Baltimore, MD USA
关键词
heart failure; kidney; creatinine; natriuretic peptides; kidney failure;
D O I
10.1161/01.CIR.0000141829.04031.25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Nesiritide (synthetic human brain natriuretic peptide) is approved for the treatment of symptomatic heart failure. However, studies of brain natriuretic peptide in patients with heart failure have come to conflicting conclusions about effects on glomerular filtration rate (GFR), effective renal plasma flow, natriuresis, and diuresis. Methods and Results-To identify a population at high risk of renal dysfunction with conventional treatment, we selected patients with a creatinine level increased from baseline (within 6 months). We examined the effects of nesiritide on GFR (measured by iothalamate clearance), renal plasma flow (measured by para-amino hippurate clearance), urinary sodium excretion, and urine output in a double-blind, placebo-controlled, crossover study. Patients received nesiritide (2 mug/kg IV bolus followed by an infusion of 0.01 mug/kg per minute) or placebo for 24 hours on consecutive days. Nesiritide and placebo data were compared by repeated-measures analysis and Student t test. We studied 15 patients with a recent mean baseline creatinine of 1.5+/-0.4 mg/dL and serum creatinine of 1.8+/-0.8 mg/dL on admission to the study. There were no differences in GFR, effective renal plasma flow, urine output, or sodium excretion for any time interval or for the entire 24-hour period between the nesiritide and placebo study days. For 24 hours, urine output was 113+/-51 mL/h with placebo and 110+/-56 mL/h with nesiritide. GFR during placebo was 40.9+/-25.9 mL/min and with nesiritide was 40.9+/-25.8. Conclusions-Nesiritide did not improve renal function in patients with decompensated heart failure, mild chronic renal insufficiency, and renal function that had worsened compared with baseline. The lack of effect may be related to renal insufficiency, hemodynamic alterations, sodium balance, severity of heart failure, or drug dose. Understanding the importance of these issues will permit effective and appropriate use of nesiritide.
引用
收藏
页码:1620 / 1625
页数:6
相关论文
共 22 条
[1]  
Abraham W T, 1998, J Card Fail, V4, P37, DOI 10.1016/S1071-9164(98)90506-1
[2]   The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure [J].
Butler, J ;
Emerman, C ;
Peacock, WF ;
Mathur, VS ;
Young, JB .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (02) :391-399
[3]   Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure [J].
Cataliotti, A ;
Boerrigter, G ;
Costello-Boerrigter, LC ;
Schirger, JA ;
Tsuruda, T ;
Heublein, DM ;
Chen, HH ;
Malatino, LS ;
Burnett, JC .
CIRCULATION, 2004, 109 (13) :1680-1685
[4]   Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. [J].
Colucci, WS ;
Elkayam, U ;
Horton, DP ;
Abraham, WT ;
Bourge, RC ;
Johnson, AD ;
Wagoner, LE ;
Givertz, MM ;
Liang, CS ;
Neibaur, M ;
Haught, WH .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04) :246-253
[5]   Short-term intravenous milrinone for acute exacerbation of chronic heart failure - A randomized controlled trial [J].
Cuffe, MS ;
Califf, RM ;
Adams, KF ;
Benza, R ;
Bourge, R ;
Colucci, WS ;
Massie, BM ;
O'Connor, CM ;
Pina, I ;
Quigg, R ;
Silver, MA ;
Georghiade, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (12) :1541-1547
[6]   Comparison of iothalamate clearance methods for measuring GFR [J].
Dowling, TC ;
Frye, RF ;
Fraley, DS ;
Matzke, GR .
PHARMACOTHERAPY, 1999, 19 (08) :943-950
[7]   Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure [J].
Gottlieb, SS ;
Skettino, SL ;
Wolff, A ;
Beckman, E ;
Fisher, ML ;
Freudenberger, R ;
Gladwell, T ;
Marshall, J ;
Cines, M ;
Bennett, D ;
Liittschwager, EB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :56-59
[8]   The prognostic importance of different definitions of worsening renal function in congestive heart failure [J].
Gottlieb, SS ;
Abraham, W ;
Butler, J ;
Forman, DE ;
Loh, E ;
Massie, BM ;
O'Connor, CM ;
Rich, MW ;
Stevenson, LW ;
Young, J ;
Krumholz, HM .
JOURNAL OF CARDIAC FAILURE, 2002, 8 (03) :136-141
[9]   RENAL, ENDOCRINE, AND HEMODYNAMIC-EFFECTS OF HUMAN BRAIN NATRIURETIC PEPTIDE IN NORMAL MAN [J].
HOLMES, SJ ;
ESPINER, EA ;
RICHARDS, AM ;
YANDLE, TG ;
FRAMPTON, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (01) :91-96
[10]   Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans [J].
Jensen, KT ;
Carstens, J ;
Pedersen, EB .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1998, 274 (01) :F63-F72